Tweet
Look, I don't mind explaining things to help people out, but c'mon and help me out here.
It has been debated for the better part of a year whether or not this drug has succeeded in phase 2b. Months and months later, it is mentioned alongside with Kybella (which has launched), and two acne drugs in late phase 3 studies. It is highlighted in the late stage aesthetic drugs. If you notice, there are 27 drugs being developed for aesthetics, but they chose deliberately to mention bimatoprost for hair growth.
If they weren't continuing with the program or planning to release it, then there would be no mention at all. Instead, it is there, right next to a drug that has already launched, and two drugs that have already been engaged in phase 3 studies.
They've also recently stated publicly that they've chosen to move forward with 70 projects, and if you notice, the total number of programs there is 70!
I've posted before about seti and bim, and this proves my ideas to be correct on the matter. They are going to be used together to tackle hair loss, and they will corner the market by doing so. One stops hair loss, the other regrows, and the result should be a complete reversal of hair loss if in the early to mid stages. It also means they are close to a release for bim.
--- That's a post I made earlier, it is proof enough. If they weren't proceeding, it wouldn't have been included in the presentation, or mentioned directly among the 27 late stage aesthetics programs. It also wouldn't have been mentioned among the 70 programs they've decided to move forward with as stated by head of Branding R&D, David Nicholson.
Being lumped together among the 70 programs they've chosen to move forward with, leaves nothing to interpretation.
Sorry, Swooping, you are dead wrong.
It has been debated for the better part of a year whether or not this drug has succeeded in phase 2b. Months and months later, it is mentioned alongside with Kybella (which has launched), and two acne drugs in late phase 3 studies. It is highlighted in the late stage aesthetic drugs. If you notice, there are 27 drugs being developed for aesthetics, but they chose deliberately to mention bimatoprost for hair growth.
If they weren't continuing with the program or planning to release it, then there would be no mention at all. Instead, it is there, right next to a drug that has already launched, and two drugs that have already been engaged in phase 3 studies.
They've also recently stated publicly that they've chosen to move forward with 70 projects, and if you notice, the total number of programs there is 70!
I've posted before about seti and bim, and this proves my ideas to be correct on the matter. They are going to be used together to tackle hair loss, and they will corner the market by doing so. One stops hair loss, the other regrows, and the result should be a complete reversal of hair loss if in the early to mid stages. It also means they are close to a release for bim.
--- That's a post I made earlier, it is proof enough. If they weren't proceeding, it wouldn't have been included in the presentation, or mentioned directly among the 27 late stage aesthetics programs. It also wouldn't have been mentioned among the 70 programs they've decided to move forward with as stated by head of Branding R&D, David Nicholson.
Being lumped together among the 70 programs they've chosen to move forward with, leaves nothing to interpretation.
Sorry, Swooping, you are dead wrong.
Comment